ATE406910T1 - Botulinustoxin bei der behandlung und prävention von akne - Google Patents

Botulinustoxin bei der behandlung und prävention von akne

Info

Publication number
ATE406910T1
ATE406910T1 AT02791543T AT02791543T ATE406910T1 AT E406910 T1 ATE406910 T1 AT E406910T1 AT 02791543 T AT02791543 T AT 02791543T AT 02791543 T AT02791543 T AT 02791543T AT E406910 T1 ATE406910 T1 AT E406910T1
Authority
AT
Austria
Prior art keywords
acne
botulinum toxin
effects
prevention
treatment
Prior art date
Application number
AT02791543T
Other languages
English (en)
Inventor
Dana Suskind
Ann Tilton
Mary Caire
Original Assignee
Univ Louisiana State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisiana State filed Critical Univ Louisiana State
Application granted granted Critical
Publication of ATE406910T1 publication Critical patent/ATE406910T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT02791543T 2001-07-27 2002-07-25 Botulinustoxin bei der behandlung und prävention von akne ATE406910T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30820501P 2001-07-27 2001-07-27

Publications (1)

Publication Number Publication Date
ATE406910T1 true ATE406910T1 (de) 2008-09-15

Family

ID=23192997

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02791543T ATE406910T1 (de) 2001-07-27 2002-07-25 Botulinustoxin bei der behandlung und prävention von akne

Country Status (15)

Country Link
US (1) US7226605B2 (de)
EP (1) EP1411978B1 (de)
JP (1) JP4138651B2 (de)
KR (1) KR100602308B1 (de)
CN (1) CN1258381C (de)
AT (1) ATE406910T1 (de)
AU (1) AU2002355730B2 (de)
CA (1) CA2451923C (de)
CY (1) CY1108605T1 (de)
DE (1) DE60228723D1 (de)
DK (1) DK1411978T3 (de)
ES (1) ES2312651T3 (de)
NZ (1) NZ531389A (de)
PT (1) PT1411978E (de)
WO (1) WO2003011333A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
EP2272340B1 (de) 2002-08-19 2018-03-14 Ira Sanders Botulinumtoxin
US20120114697A1 (en) 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US7666435B2 (en) * 2002-08-19 2010-02-23 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
MXPA05009424A (es) 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Tratamiento de chalazion cronico y hordeolum con la toxina botulinica.
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
GB0328060D0 (en) * 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US9078892B2 (en) 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
LT2985039T (lt) * 2004-03-03 2018-11-12 Revance Therapeutics, Inc. Botulino toksinų vietinis taikymas ir jų įvedimas per odą
WO2005120546A2 (en) 2004-03-03 2005-12-22 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US20050220821A1 (en) 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US6991789B2 (en) 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
US7179474B2 (en) 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7897147B2 (en) 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
JP2008531732A (ja) 2005-03-03 2008-08-14 ルバンス セラピュティックス インク． ボツリヌス毒素の局所塗布及び経皮送達のための組成物及び方法
US7419675B2 (en) 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
CN103315954A (zh) 2005-07-18 2013-09-25 麻萨诸塞州洛厄尔大学 制备与使用纳米乳剂的组合物和方法
BRPI0619134B8 (pt) 2005-12-01 2021-05-25 Univ Massachusetts Lowell nanoemulsão, composição farmacêutica, composição, métodos cosméticos para o tratamento de rugas, linhas faciais e/ou linhas do pescoço, e de retardar o início das rugas, linhas faciais e/ou linhas do pescoço, e, método de fabricação de uma nanoemulsão
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US7824694B2 (en) 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US9061025B2 (en) 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
AU2007353340A1 (en) 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor
AU2007329579A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
KR20090096735A (ko) * 2006-12-29 2009-09-14 레반스 테라퓨틱스, 아이엔씨. Ｈｉｖ-ｔａｔ로부터 유래된 폴리펩티드 단편에 의해 안정화된 보툴리눔 독소의 국소 적용 및 경피 전달용 조성물 및 방법
WO2008082885A2 (en) * 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Transport molecules using reverse sequence hiv-tat polypeptides
CN103961315A (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
BRPI0914630A2 (pt) 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
EP2480250B1 (de) 2009-09-24 2014-04-16 Allergan, Inc. Zusammensetzungen Botulinumtoxin A oder B enthaltend zur Verwendung bei der Behandlung der Osteoporose
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP2649984A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose
EP2836193B1 (de) 2012-04-13 2018-01-31 Lubrizol Advanced Materials, Inc. Verbindungen zur hemmung neuronaler exozytose (ii)
EP2649985A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (III)
EP2649983A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (II)
ES2612237T3 (es) 2013-03-22 2017-05-12 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, membranas de mucosas y/o uñas
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
WO2015168564A1 (en) 2014-05-01 2015-11-05 Anterios, Inc. Methods to treat, prevent, and improve skin conditions
WO2015168562A1 (en) * 2014-05-01 2015-11-05 Anterios, Inc. Demonstrable efficacy across or within patient populations
WO2016154020A1 (en) * 2015-03-20 2016-09-29 The Regents Of The University Of California Methods for reducing sebum production and/or excretion
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
EP3470054B1 (de) 2017-10-11 2023-09-20 Hugel Inc. Mikrostrukturformulierungstechniken für botulinumtoxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
RU2020123343A (ru) * 2017-12-20 2022-01-20 Аллерган, Инк. Полипептиды клеточносвязывающего домена ботулинического токсина и способы применения для омоложения кожи
WO2019226599A1 (en) * 2018-05-22 2019-11-28 Alkalidx, Inc. Diagnostics and treatments of anesthetic insensitive subjects
US11191819B2 (en) 2018-08-28 2021-12-07 Ira Sanders Skin therapeutics
EP3825689A3 (de) 2018-11-29 2021-09-15 Hugel Inc. Zellbasiertes verfahren zur bestimmung der aktivität von botulinumtoxin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4885282A (en) * 1987-07-02 1989-12-05 Thornfeldt Carl R Treatment of hyperhidrosis, ichthyosis and wrinkling
US6939852B2 (en) * 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
BR9607143A (pt) * 1995-03-16 1997-11-25 Knoll Ag Enzima ibtenível de clostridium histolyticum mistura de enzimas uso da mistura uso de enzimas colagenase hp na forma pura colagenase az na forma pura e elastase na forma pura
AU1706400A (en) * 1998-10-27 2000-05-15 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20030021775A1 (en) * 2001-07-27 2003-01-30 Ramot University Authority For Applied Research & Industrial Development Ltd. Device for and method of controlled enzymatic removal and retrieval of tissue
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
EP2272340B1 (de) * 2002-08-19 2018-03-14 Ira Sanders Botulinumtoxin

Also Published As

Publication number Publication date
PT1411978E (pt) 2008-11-28
JP2004538310A (ja) 2004-12-24
KR100602308B1 (ko) 2006-07-18
CN1543354A (zh) 2004-11-03
CA2451923C (en) 2009-10-20
EP1411978A4 (de) 2005-08-17
WO2003011333A1 (en) 2003-02-13
US7226605B2 (en) 2007-06-05
EP1411978B1 (de) 2008-09-03
KR20040030820A (ko) 2004-04-09
EP1411978A1 (de) 2004-04-28
NZ531389A (en) 2005-08-26
CY1108605T1 (el) 2014-04-09
AU2002355730B2 (en) 2007-09-13
ES2312651T3 (es) 2009-03-01
DK1411978T3 (da) 2009-01-05
CN1258381C (zh) 2006-06-07
CA2451923A1 (en) 2003-02-13
US20050074466A1 (en) 2005-04-07
JP4138651B2 (ja) 2008-08-27
DE60228723D1 (de) 2008-10-16

Similar Documents

Publication Publication Date Title
ATE406910T1 (de) Botulinustoxin bei der behandlung und prävention von akne
DE69931766D1 (de) Antitumorale mittel
DE69710224T2 (de) Behandlung von neurodegenerativen zuständen mittels nimesulide
WO2003088908A3 (en) Heterocyclo inhibitors of potassium channel function
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
ATE518537T1 (de) Selective androgen-rezeptor-modulatoren (sarms) für die behandlung der benignen prostatahyperplasie
DK0724444T3 (da) Fremgangsmåde til behandling af androgen alopecia med inhibitorer for 5-alfa-reduktase
ATE515253T1 (de) Zusammensetzungen auf basis von etyllinoleat und triethylcitrat zur behandlung von seborrhöe und akne
ATE234089T1 (de) Zubereitungen enthaltend sclareol und sclareolide zur behandlung mikrobieller infektionen
DE60216300D1 (de) Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
DE60132008D1 (de) Cethylmyristat und cetylpalmitat zurbehandlung von ekzemen und/oder psoriasis
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
DE69936307D1 (de) Verringerung der homocysteinkonzentration im serum mittels allium und vitaminen
ATE238803T1 (de) Pphospholipidkomplexe von proanthocyanidin a2 als antiatherosklerotische mittel
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE293972T1 (de) Behandlung von chronischen schmerzen
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
MX9203739A (es) Complejo organico de oro aplicado topicamente.
SE9904059D0 (sv) Serine protease and topical retinoid compositions
ATE365718T1 (de) Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten
ATE390144T1 (de) Behandlung von fibrosen
FR2709963B1 (fr) Composition dermocosmétique, antifongique, notamment utile dans le traitement de dermites séborréhiques.
AU2003266031A1 (en) Pomolic acid, its isomers, derivatives and their uses, pharmaceutical composition method to prepare the pharmaceutical composition and method for treating multidrug resistant tumours
BR0312402A (pt) Utilização de inibidores seletivos de ciclooxigenase-2 e agentes trombolìticos para o tratamento ou prevenção de um episódio vaso-oclusivo

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1411978

Country of ref document: EP